Abstract
Results of the ARBITER 6–HALTS trial indicate a superiority of the lipid-modifying agent nicotinic acid over ezetimibe for the treatment of atherosclerotic lesions. These findings could have substantial implications for patients worldwide who remain at moderate to high risk of cardiovascular complications because of low levels of HDL cholesterol. But is the evidence substantiated?
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
